CASE REPORT

A 33-year-old, married woman came to the hospital in 2015 with bleeding from the vagina and shortness of breath of 3 months’ duration. Her obstetric history was as follows: the first pregnancy ended in a miscarriage, the second was a stillbirth, and the third was a molar pregnancy. She delivered a healthy girl after her fourth pregnancy 4 years ago. At presentation, her beta human chorionic gonadotropin (hCG) level was 450,000 mIU/mL, an ultrasound of the abdomen showed a 7 cm × 6 cm × 5 cm cystic mass in the endometrial cavity, a chest radiograph and a computed tomography scan of the chest showed multiple lung metastases, and magnetic resonance imaging of the brain showed hemorrhagic metastasis.

The patient was diagnosed with gestational trophoblastic tumor (GTT) and stage IV choriocarcinoma, with a WHO risk score of 20. A regimen of etoposide and cisplatin with etoposide, methotrexate, and dactinomycin (EMA-EP) was initiated, after which her hCG level declined in a logarithmic linear fashion, and the lung metastases resolved. However, after the seventh cycle of EMA-EP, her hCG level started rising. She was subsequently treated with combination chemotherapy comprising paclitaxel, ifosfamide, and cisplatin. Although the hCG level declined to a normal level after the second cycle, the patient developed life-threatening toxicity with grade IV neutropenic sepsis with liver and renal dysfunction. She refused further intravenous chemotherapy and was monitored without treatment. A month later, her hCG level was abnormal and a radiograph of her chest showed metastases.

The patient declined further intensive treatment, so she was prescribed oral etoposide 50 mg/day for 7 days every 3 to 4 weeks. After six cycles, she was in biochemical remission with a normal computed tomography scan of the chest and brain. She was treated with two more cycles of etoposide and she is currently well without any evidence of disease.

DISCUSSION

High-risk GTT is usually treated with combination chemotherapy. However, approximately 20% of patients have a recurrence of disease after initial treatment. These patients are treated with second-line chemotherapy consisting of various combinations of drugs (eg, EMA-EP; vinblastine sulfate, ifosfamide, and cisplatin; paclitaxel, ifosfamide, and cisplatin; ifosfamide, carboplatin, and etoposide). The agents that have shown response in refractory GTT include ifosfamide, gemcitabine, and capecitabine. Ifosfamide alone or in combination (eg, combined etoposide, ifosfamide, and cisplatin) are active in patients with refractory disease. Gemcitabine plus cisplatin has shown activity in a patient who progressed after combination chemotherapy and EP-EMA. Ifosfamide alone can produce complete and long-lasting remission in refractory GTT. If there is biochemical remission, then it could be consolidated with high-dose chemotherapy supported with peripheral blood stem cells.

To the best of our knowledge, this is the first case of refractory GTT showing complete remission with oral etoposide without any significant toxicity. Etoposide, a topoisomerase II inhibitor, is a drug specific to cell-cycle phase and is active when given orally to maintain a cytotoxic trough level. It was not administered continuously in this patient because of previous toxicity; however, it could be considered to represent metronomic treatment. Metronomic chemotherapy has not been previously used in refractory choriocarcinoma. Systematic analysis has shown that metronomic chemotherapy is effective and safe in a broad range of tumors. The mechanism of action of metronomic chemotherapy is probably due to the effect on stromal components within a tumor. It had been thought that metronomic chemotherapy targeted angiogenesis, but recent data have shown that metronomic chemotherapy targets activated endothelial cells and decreases the chance of developing acquired drug resistance.
In conclusion, oral etoposide is an active agent in the treatment of refractory choriocarcinoma. Further phase II studies are indicated.

AUTHOR CONTRIBUTIONS
Manuscript writing: All authors
Final approval of manuscript: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.

Manikandan Dhanushkodi
No relationship to disclose
Trivadi Ganesan
No relationship to disclose
Tenali Gnana Sagar
No relationship to disclose

Affiliations
Manikandan Dhanushkodi, Trivadi Ganesan, Tenali Gnana Sagar, Cancer Institute (WIA), Chennai, India.

REFERENCES
1. Alifrangis C, Agarwal R, Short D, et al: EMA/CO for high-risk gestational trophoblastic neoplasia: Good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 31:280-286, 2013
2. Han SN, Amant F, Leunen K, et al: EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and actinomycin) in a series of 18 women with gestational trophoblastic neoplasia. Int J Gynecol Cancer 22:875-880, 2012
3. Lurain JR, Nejad B: Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol 97:618-623, 2005
4. Sutton GP, Soper JT, Blessing JA, et al: Ifosfamide alone and in combination in the treatment of refractory malignant gestational trophoblastic disease. Am J Obstet Gynecol 167:489-495, 1992
5. Pandian Z, Seck M, Smith R, et al: Gestational choriocarcinoma: An unusual presentation with response to gemcitabine and surgery. BJOG 111:382-384, 2004
6. Bianconi M, Jankilevich G, Otero S, et al: Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine. Gynecol Oncol 106:268-271, 2007
7. El-Helw LM, Seck M, Haynes R, et al: High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. Br J Cancer 93:620-621, 2005
8. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
9. Lien K, Georgsdottir S, Sivanathan L, et al: Low-dose metronomic chemotherapy: A systematic literature analysis. Eur J Cancer 49:3387-3395, 2013
10. Scharovsky OG, Mainetti LE, Rozados VR: Metronomic chemotherapy: Changing the paradigm that more is better. Curr Oncol 16:7-15, 2009
11. Matti R: Metronomic chemotherapy. J Pharmacol Pharmacother 5:186-192, 2014